News Sentiment

OKUR sentiment intelligence

OnKure Therapeutics, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 39 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 4.28 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 31

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-6.6% over one week, +1.9% over four weeks, trend active, and near fair-value range.

Latest direct headline Neutral

Enterprise value to revenue forward of OnKure Therapeutics, Inc. – NASDAQ:OKUR

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction -6.6% Price reacting lower
Trend fit Trend active 1.9% over four weeks
Fair value -14.4% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 10
Neutral 27
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 31
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 8
Stock Titan 6
TradingView 4
simplywall.st 4
GlobeNewswire 4
MarketBeat 2
DonanımHaber 2
Investing.com 2

Event Lens

What the news is about

Classified themes
Market update 19
Earnings 12
Deals and strategy 7
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 39
Stock Titan Direct company coverage

OnKure Therapeutics (NASDAQ: OKUR) registers 36.1M shares for resale

OnKure Therapeutics (NASDAQ: OKUR) has filed an S-3 shelf registration statement to allow selling shareholders to resell up to 36.1 million shares of Class A common stock. This includes 26.7 million existing shares and 9.4 million shares issuable upon the exercise of pre-funded w

Tone
Neutral 50/100
Event
Market update
Published
24 Apr 2026 20:10
Source
Stock Titan
Stock Titan Direct company coverage

OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million

OnKure Therapeutics has completed its merger with Reneo Pharmaceuticals and a concurrent $65 million private placement, with the combined company now trading on Nasdaq as OKUR. This transaction provides OnKure with approximately $139 million in cash, extending its operational run

Tone
Positive 75/100
Event
Deals and strategy
Published
03 Mar 2026 02:52
Source
Stock Titan